News|Articles|September 2, 2005

Pharmaceutical Technology

  • Pharmaceutical Technology-09-02-2005
  • Volume 29
  • Issue 9

Reshaping CMC Development Services

Author(s)Jim Miller

A summertime burst of acquisition activity in CMC development services prompts the question: a coincidence of timing or the start of a trend?


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.